Compare Public Service Enterprise Group Incorporated Common Stock (PEG) vs SELLAS Life Sciences Group Inc. Common Stock (SLS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Public Service Enterprise Group Incorporated Common Stock vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Public Service Enterprise Group Incorporated Common Stock trades at $69.9 (market cap $35.12B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.93 (market cap $2.51B). The key difference: Public Service Enterprise Group Incorporated Common Stock is far larger — about 14× SELLAS Life Sciences Group Inc. Common Stock's market cap, and Public Service Enterprise Group Incorporated Common Stock pays a 3.8% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Public Service Enterprise Group Incorporated Common Stock for 0 Days and SELLAS Life Sciences Group Inc. Common Stock for 0 Days on average.
| PEG | SLS | |
|---|---|---|
Market Cap | $35.12B | $2.51B |
Volume | 4,400,164 | 6,359,048 |
Sector | Utilities | Health |
52-Week High | $86.95 | $15.46 |
52-Week Low | $66.56 | $1.39 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $59.61B | $2.37B |
Dividend Yield | 3.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Public Service Enterprise Group (PEG) trades at $70.47, down 0.41% on the day, showing neutral technical signals with support at $70 and resistance at $71. The company maintains solid fundamentals with a 17.53 P/E ratio and consistent earnings beats in recent quarters, though Q3 2026 results are pending. Revenue grew to $12.17B in 2025 with a healthy 16.04% net income margin, while analyst consensus remains mixed with a $83.40 price target suggesting potential upside.
PEG presents a stable utility investment with regulated growth and nuclear assets supporting a 6-8% earnings outlook. Key risks include regulatory approvals for capex plans and interest rate sensitivity. Institutional buying and a 15-year dividend growth streak add appeal, but recent CEO stock sales and proximity to 52-week lows warrant caution amid sector volatility.
SELLAS Life Sciences (SLS) trades at $12.41, up 4.02% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported no revenue in 2025, with a net loss of $26.86 million, negative ROE and ROA, and a high P/B ratio of 18.2. Recent news includes a law firm investigation into investor claims and positive preclinical data for SLS009 in pancreatic cancer models presented at the AACR conference.
The outlook hinges on upcoming clinical trial results, particularly the Phase 3 REGAL trial for GPS in AML, with topline data expected in Q4 2026. While analyst consensus is unanimously bullish, significant risks include the binary nature of trial outcomes, ongoing legal scrutiny, and persistent negative profitability metrics. The stock's recent surge of ~300% year-to-date reflects high investor optimism but also heightened volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Public Service Enterprise Group Incorporated Common Stock
Public Service Enterprise Group Incorporated is a New Jersey-based utility holding company operating through Public Service Electric and Gas Co. (PSE&G), which transmits and distributes electricity and distributes natural gas, and PSEG Power, which operates the Salem and Hope Creek nuclear generating stations. It also runs the Long Island Power Authority's electric system under contract via PSEG Long Island.
Read more on PEG →About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →
